Optimising	optimising	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
prevention	prevention	O	O	O	O
in	in	O	O	O	O
non-valvular	non-valvular	O	O	O	O
atrial	atrial	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Atrial	atrial	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
is	is	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
substantial	substantial	O	O	O	O
morbidity	morbidity	O	O	O	O
and	and	O	O	O	O
mortality	mortality	O	O	O	O
.	.	O	O	O	O

Pooled	pooled	O	O	O	O
data	data	O	O	O	O
from	from	O	O	O	O
trials	trials	O	O	O	O
comparing	comparing	O	O	O	O
antithrombotic	antithrombotic	O	O	O	O
treatment	treatment	O	O	O	O
with	with	O	O	O	O
placebo	placebo	O	O	O	O
have	have	O	O	O	O
shown	shown	O	O	O	O
that	that	O	O	O	O
warfarin	warfarin	CHEMICALS	O	OTHERS	I
reduces	reduces	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
stroke	stroke	O	DISEASE	OTHERS	I
by	by	O	O	O	O
62	62	O	O	O	O
%	%	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
that	that	O	O	O	O
aspirin	aspirin	CHEMICALS	O	OTHERS	I
alone	alone	O	O	O	O
reduces	reduces	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
by	by	O	O	O	O
22	22	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Overall	overall	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
high-risk	high-risk	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
warfarin	warfarin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
superior	superior	O	O	O	O
to	to	O	O	O	O
aspirin	aspirin	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
preventing	preventing	O	O	O	O
strokes	strokes	O	DISEASE	OTHERS	I
,	,	O	O	O	O
with	with	O	O	O	O
a	a	O	O	O	O
relative	relative	O	O	O	O
risk	risk	O	O	O	O
reduction	reduction	O	O	O	O
of	of	O	O	O	O
36	36	O	O	O	O
%	%	O	O	O	O
.	.	O	O	O	O

Ximelagatran	ximelagatran	O	O	OTHERS	I
,	,	O	O	O	O
an	an	O	O	O	O
oral	oral	O	O	O	O
direct	direct	O	O	OTHERS	I
thrombin	thrombin	O	O	OTHERS	I
inhibitor	inhibitor	O	O	OTHERS	I
,	,	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
as	as	O	O	O	O
efficient	efficient	O	O	O	O
as	as	O	O	O	O
vitamin	vitamin	CHEMICALS	O	OTHERS	I
K	k	CHEMICALS	O	OTHERS	I
antagonist	antagonist	O	O	O	O
drugs	drugs	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
of	of	O	O	O	O
embolic	embolic	O	O	OTHERS	I
events	events	O	O	OTHERS	I
,	,	O	O	O	O
but	but	O	O	O	O
has	has	O	O	O	O
been	been	O	O	O	O
recently	recently	O	O	O	O
withdrawn	withdrawn	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
abnormal	abnormal	O	O	OTHERS	I
liver	liver	O	O	OTHERS	I
function	function	O	O	OTHERS	I
tests	tests	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
ACTIVE-W	active-w	O	O	O	O
(	(	O	O	O	O
Atrial	atrial	O	DISEASE	OTHERS	I
Fibrillation	fibrillation	O	DISEASE	OTHERS	I
Clopidogrel	clopidogrel	CHEMICALS	O	OTHERS	I
Trial	trial	O	O	O	O
with	with	O	O	O	O
Irbesartan	irbesartan	O	O	OTHERS	I
for	for	O	O	O	O
Prevention	prevention	O	O	O	O
of	of	O	O	O	O
Vascular	vascular	O	O	OTHERS	I
Events	events	O	O	OTHERS	I
)	)	O	O	O	O
study	study	O	O	O	O
has	has	O	O	O	O
demonstrated	demonstrated	O	O	O	O
that	that	O	O	O	O
warfarin	warfarin	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
superior	superior	O	O	O	O
to	to	O	O	O	O
platelet	platelet	O	O	O	O
therapy	therapy	O	O	O	O
(	(	O	O	O	O
clopidogrel	clopidogrel	CHEMICALS	O	OTHERS	I
plus	plus	O	O	O	O
aspirin	aspirin	CHEMICALS	O	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
prevention	prevention	O	O	O	O
af	af	O	O	OTHERS	I
embolic	embolic	O	O	OTHERS	I
events	events	O	O	OTHERS	I
.	.	O	O	O	O

Idraparinux	idraparinux	O	O	OTHERS	I
,	,	O	O	O	O
a	a	O	O	O	O
Factor	factor	CHEMICALS	O	OTHERS	I
Xa	xa	CHEMICALS	O	OTHERS	I
inhibitor	inhibitor	O	O	O	O
,	,	O	O	O	O
is	is	O	O	O	O
being	being	O	O	O	O
evaluated	evaluated	O	O	O	O
in	in	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
atrial	atrial	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Angiotensin-converting	angiotensin-converting	O	O	O	O
enzyme	enzyme	CHEMICALS	O	OTHERS	I
inhibitors	inhibitors	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
angiotensin	angiotensin	CHEMICALS	O	OTHERS	I
II	ii	CHEMICALS	O	OTHERS	I
receptor-blocking	receptor-blocking	O	O	O	O
drugs	drugs	O	O	O	O
hold	hold	O	O	O	O
promise	promise	O	O	O	O
in	in	O	O	O	O
atrial	atrial	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
through	through	O	O	O	O
cardiac	cardiac	O	O	OTHERS	I
remodelling	remodelling	O	O	OTHERS	I
.	.	O	O	O	O

Preliminary	preliminary	O	O	O	O
studies	studies	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
statins	statins	CHEMICALS	O	OTHERS	I
could	could	O	O	O	O
interfere	interfere	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
recurrence	recurrence	O	O	O	O
after	after	O	O	O	O
electrical	electrical	O	O	O	O
cardioversion	cardioversion	O	O	O	O
.	.	O	O	O	O

Finally	finally	O	O	O	O
,	,	O	O	O	O
percutaneous	percutaneous	O	O	O	O
methods	methods	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
exclusion	exclusion	O	O	O	O
of	of	O	O	O	O
left	left	O	O	O	O
atrial	atrial	O	O	O	O
appendage	appendage	O	O	O	O
are	are	O	O	O	O
under	under	O	O	O	O
investigation	investigation	O	O	O	O
in	in	O	O	O	O
high-risk	high-risk	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

